FindTrial
Sign In

swedish orange

DRUG2 trials

Sponsors

Eip Pharma Inc., UZ Brussel

Conditions

2017)Procalcitonin concentration ≥0·5 ng/mL or white blood cell count ≥12×10^9 per L (all without other plausible sourceSubjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by consensus criteria (McKeith et alUrinary tract infection with systemic involvement (UTI: definiteattributable to the UTI: • Temperature ≥38°C • Flank pain or costovertebral angle tenderness • Systolic blood pressure <90 mmHg without alternative cause • Significant elevation of inflammatory markers related to the UTI: o C-reactive protein concentration ≥50 mg/Lbased on at least history and examination). • Bacteraemia with the same pathogen as isolated from urine culturebut the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD)including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negative

Phase 2

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
CompletedCTIS2023-504373-20-00
Eip Pharma Inc.2017), but the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD), including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negative +2
Start: 2023-08-09End: 2025-05-12Target: 15Updated: 2025-03-25

Phase 3

A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement.
Not yet recruitingCTIS2025-524703-76-00
UZ Brusselattributable to the UTI: • Temperature ≥38°C • Flank pain or costovertebral angle tenderness • Systolic blood pressure <90 mmHg without alternative cause • Significant elevation of inflammatory markers related to the UTI: o C-reactive protein concentration ≥50 mg/L, based on at least history and examination). • Bacteraemia with the same pathogen as isolated from urine culture, or possible UTI according to the diagnostic criteria of the research reference standard for UTI proposed by Bilsen et al (see reference 19 in protocol)). Systemic involvement: one or more of the following +3
Target: 264Updated: 2026-05-12